In the OCTANE/A5208 study of initial antiretroviral therapy (ART) in women exposed to single-dose nevirapine (sdNVP) ≥6 mo earlier, the primary endpoint (virological failure or death) was significantly more frequent in the NVP-containing treatment arm than in the lopinavir/ritonavir-containing treatment arm. Detection of NVP resistance in plasma virus at study entry by standard population genotype was strongly associated with the primary endpoint in the NVP arm, but two-thirds of endpoints occurred in women without NVP resistance. We hypothesized that low-frequency NVP-resistant mutants, missed by population genotype, explained excess failure in the NVP treatment arm. Plasma samples from 232 participants were analyzed by allele-specific PCR at study entry to quantify NVP-resistant mutants down to 0.1% for 103N and 190A and to 0.3% for 181C. Of 201 women without NVP resistance by population genotype, 70 (35%) had NVP-resistant mutants detected by allele-specific PCR. Among these 70 women, primary endpoints occurred in 12 (32%) of 38 women in the NVP arm vs. 3 (9%) of 32 in the lopinavir/ritonavir-containing arm (hazard ratio = 3.84). The occurrence of a primary endpoint in the NVP arm was significantly associated with the presence of K103N or Y181C NVP-resistant mutations at frequencies >1%. The risk for a study endpoint associated with NVP-resistant mutant levels did not decrease with time. Therefore, among women with prior exposure to sdNVP, low-frequency NVP-resistant mutants were associated with increased risk for failure of NVP-containing ART. The implications for choosing initial ART for sdNVP-exposed women are discussed.
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mother-to-child transmission | nonnucleoside reverse transcriptase inhibitors S ingle-dose nevirapine (sdNVP) administered at the onset of labor to pregnant HIV-infected women can reduce the risk for mother-to-child transmission (MTCT) of HIV by ∼50% (1-3), but NVP-resistant HIV-1 mutants emerge in the majority of women who have received sdNVP alone (4, 5) . These mutants most commonly encode K103N, Y181C, or G190A mutations in HIV-1 RT, conferring resistance to NVP and efavirenz. With the use of sensitive drug resistance assays, such as allele-specific PCR (ASP), resistant mutants can be detected in the majority of women after NVP exposure and can persist for years (6, 7) .
In resource-limited settings, NVP in combination with lamivudine (3TC) and zidovudine (AZT) or tenofovir disoproxil fumarate (TDF) is recommended as the standard of care for first-line antiretroviral therapy (ART) (8) . This recommendation is potentially problematic for women who have been previously exposed to sdNVP (9) (10) (11) . The A5208/OCTANE trials were designed to compare protease inhibitor-based therapy using lopinavir/ritonavir (LPV/r) with NVP-based therapy in ART-naive women with or without prior sdNVP. A5208 trial 1, which will be the focus of this report, showed that LPV/r + TDF and emtricitabine (FTC) was superior to NVP + TDF/FTC (P = 0.001) for initial therapy of women with prior sdNVP ≥6 mo earlier and a CD4 cell count <200 cells/mm 3 (12) . Standard genotype analysis of stored pretherapy plasma samples revealed NVP resistance mutations in 13% of women in the NVP arm, 73% of whom experienced the primary study endpoint of virological failure or death. However, NVP resistance was detected by standard genotype in only 35% of women experiencing a primary endpoint in the NVP arm. We hypothesized that the excess of endpoints in the NVP arm was attributable to low-frequency NVP-resistant mutants that compromised the effectiveness of the NVP-based regimen. To test this hypothesis, we used ASP to quantify NVP-resistant mutants in study subjects at entry into A5208/OCTANE trial 1.
Results

Trial 1 Primary Study Results.
The results of the primary analysis of trial 1 (12) , stratified by standard population genotype result at study entry for NVP resistance, are summarized in Fig. 1A . Of the 241 women enrolled in trial 1, 42 women reached a primary endpoint (death or virological failure); about three-quarters of these were in the NVP arm. The distribution of deaths and failures was similar in the two arms: four deaths of 32 endpoints in the NVP arm compared with one death of 9 endpoints in the LPV/r arm (12) . Of the 239 women for whom population genotypes were obtained at baseline, 33 had NVP resistance mutations: 15 (13%) of 120 women in the NVP arm and 18 (15%) of 119 women in the LPV/r arm.
Among women with NVP resistance at baseline, 11 (73%) of 15 experienced a primary endpoint in the NVP arm compared with 1 (6%) of 18 in the LPV/r arm [hazard ratio (HR) = 18.14 (95% confidence interval [CI]: 2.26-145.37); P = 0.006; Fig. 1A ]. However, nearly two-thirds (21 of 32) of the endpoints in the NVP arm occurred in patients without baseline NVP resistance by population genotype (Fig. 1B) . Among women without baseline NVP resistance, more than twice as many women in the NVP arm (19%) compared with the LPV/r arm (9%) reached a primary endpoint [HR = 2.33 (95% CI: 1.05-5.20); P = 0.038]. Therefore, prior sdNVP was associated with increased risk of a primary endpoint even among women with no NVP resistance detected by population genotype, leading to the hypothesis that low-frequency NVP-resistant variants might contribute to greater risk of virological failure or death.
Sample Analysis by ASP. Baseline plasma samples from 234 subjects were available for testing by ASP; the majority (73%) were infected with HIV-1 subtype C. The remaining participants had varying subtypes: 13% had subtype A1, 6% had subtype D, 0.4% had subtype A2D, and 7% had complex subtypes. ASP results were obtained from 232 samples tested (Table 1) . Indeterminate results were reported by ASP for 2 subjects at codon 103, 7 at codon 181, and 6 at codon 190 ( Table 1) .
Detection of Mutations by ASP. ASP detected NVP resistance in baseline samples from 43% of the subjects (three times the number detected by population genotype) ( Table 1) , most commonly 103N, either alone or in combination with 181C or 190A. The 181C mutant was detected in 10% of the subjects, more than half of whom also had the 103N mutation. The 190A mutation was detected in 11% of women. The median mutant frequency was highest for 103N at 4.6% and was 0.9% and 0.6% for 190A and 181C, respectively. There were no significant differences in baseline mutation frequencies between treatment arms (Fig. 2) .
Association of Baseline NVP Resistance by ASP and Primary Study
Endpoints. We conducted two separate analyses of the association between baseline NVP resistance detected by ASP and primary study endpoints ( Indeterminate result denotes ASP assay failure at that codon. NA, not applicable. *Detection limit of the assay, assuming >1,000 copies of cDNA were amplified in each of two wells in the first round. Six samples contained fewer amplifiable copies, and the sensitivity was adjusted accordingly.
232 subjects tested by ASP. Among the 51 women with detectable NVP resistance by ASP in the NVP arm, 41% experienced a primary endpoint compared with 14% of the 63 women without NVP resistance [HR = 3.30 (95% CI: 1.48-7.39); P = 0.004]. In the LPV/r treatment arm, by contrast, there was no association between baseline NVP resistance and outcome: 8% with NVP resistance by ASP experienced a primary endpoint compared with 9% who had no NVP resistance detected [HR = 0.99 (95% CI: 0.28-3.56); P = 0.99].
In the second analysis, we included only subjects (n = 201) who were negative for baseline NVP resistance by population genotype. In the NVP arm (n = 100), ASP detected NVP resistance in 38 of these women. Primary endpoints occurred in 20 women in the NVP arm, 12 (60%) of whom were determined to be NVP-resistant by ASP compared with 8 (13%) of the 62 women without NVP resistance [HR = 2.71 (95% CI: 1.08-6.80; P = 0.033]. In the LPV/r arm (n = 101), 32 women had NVP resistance detected, of whom 9% experienced a primary endpoint, identical to the proportion of the 69 women experiencing an endpoint (9%) in whom no resistance mutations were detected [HR = 1.10 (95% CI: 0.27-4.45); P = 0.90]. In both analyses, the association between baseline NVP resistance by ASP and primary study endpoints in the NVP arm remained significant after adjusting for baseline HIV-1 RNA copies/mL and CD4 cells/mm 3 at study entry (not shown).
Association of Specific NVP Resistance Mutation with Study Endpoints. We next evaluated the association between specific NVP resistance mutations at baseline and primary endpoints ( Table  3 ). The 103N mutation was the most frequent mutation identified in both treatment arms, and 40% of the women in the NVP arm with the K103N mutation reached a primary endpoint compared with 17% of women without 103N [HR = 2.53 (95% CI: 1.19-5.40); P = 0.016]. Although the 181C mutation was not as frequent as the 103N mutation at baseline, it was also strongly associated with primary endpoints in the NVP arm. Specifically, 77% of the women with the baseline 181C mutation experienced a primary endpoint in the NVP arm compared with only 19% of women without 181C [HR = 7.10 (95% CI: 3.01-16.78); P < 0.0001]. The stronger association of 181C with primary endpoints may be explained by the higher level of NVP resistance conferred by 181C than by 103N. In contrast, there was no difference in treatment outcome associated with the baseline 103N or 181C mutation in the LPV/r arm (P = 0.75 and P = 0.67, respectively). The 190A mutation was not associated with outcome in either treatment arm (P > 0.5; Table 3 ).
Risk of Endpoint by Mutant Frequency. To assess the impact of mutant frequency on risk of failure, the 51 subjects with NVP resistance detected by ASP in the NVP arm were divided into three groups by the sum of the mutant frequencies at 103N, 181C, and 190A (0.1-<1%, n = 18; 1-10%, n = 18; and >10%, n = 15), and outcome was compared across these three groups and with the subgroup with a negative ASP (Fig. 3 ). This analysis shows that the 33 women with NVP-resistant mutants in the 1-10% and >10% categories had significantly greater risk of failure than the 63 women who had no NVP resistance identified at baseline (P = 0.003). The proportion experiencing primary endpoints among women with 0.1-<1% mutant was higher [27.8% (5 of 18)] than in the subjects without mutations detected [14.3% (9 of 63)], but this difference was not significant (P = 0.26).
Risk of Endpoint by Time Since sdNVP Exposure. It has previously been reported that the risk of virological failure of NVPcontaining ART declines with time since sdNVP treatment (9-11). It has been unclear whether this observation reflects a decline in the frequency of mutations with time or some other time-related effect. To assess the relationship between risk of failure in the NVP arm and time since sdNVP exposure, women in the NVP arm with NVP resistance detected by ASP were divided into three subgroups according to time since sdNVP. In the first group of women who had received sdNVP between 6 mo and 1 y before study enrollment, 25 (63%) of 40 women had baseline NVP resistance and 44% of these women reached a primary endpoint. In the second group of women who were exposed to sdNVP 1-<2 y before enrollment, 17 (39%) of 44 women had baseline NVP resistance and 35% of these reached a primary endpoint. In the third group of women who had sdNVP ≥2 y before enrollment, 9 (30%) of 30 women had baseline NVP resistance and 44% of these reached a primary endpoint. Although the number of women with baseline NVP resistance detected by ASP declined with time since sdNVP exposure, there was no apparent decrease in risk of a primary endpoint if NVP-resistant mutants were detectable (Fig. 4) . To explore the relationship between risk of a primary endpoint in the NVP arm and time since sdNVP further, a Cox proportional hazards model was fitted, including time since sdNVP and NVP resistance detected by ASP as predictor variables (Table 4 ). This analysis showed no significant influence of time since sdNVP on the risk of a primary endpoint associated with NVP resistance at baseline after adjusting for NVP resistance and confirms the initial analysis described above. In addition, if time is coded as 1 (6 mo to <1 y), 2 (1-<2 y), and 3 (>2 y) and treated as a continuous variable, we still find a nonsignificant association with time since sdNVP exposure (P = 0.23) and risk of primary endpoint.
Nevertheless, when the 63 women in the NVP treatment arm who did not have NVP-resistant virus detected by ASP were divided into the same three subgroups according to time since sdNVP, there was a trend toward declining risk for a study endpoint with time since sdNVP treatment. Specifically, the proportions reaching a primary endpoint among women without NVP resistance detected by ASP were 27% (4 of 15), 19% (5 of 27), and 0% (0 of 21) for the subgroups with prior sdNVP exposure occurring 6 mo to <1 y, 1-<2 y, and ≥2 y before study entry, respectively (P = 0.03). This result raises the possibility of a time-dependent relationship between sdNVP and risk of a study endpoint that is not explained by the ASP results.
Discussion
Improved prediction of treatment outcome in HIV-1-infected women receiving treatment with NVP-containing ART is important in resource limited settings, where sdNVP has been used widely for prevention of MTCT and where virus load monitoring and second-line treatment options are very limited. Following sdNVP, high drug concentrations and slow drug clearance (13) result in the selection of NVP-resistant mutants that become the dominant virus population in most women. Although this resistant virus population decays to lower levels over time (4) , resistant mutants can still be detected in a substantial fraction of patients after 1 y and persist in some women for longer (6, 7) . The current study shows that women with NVP-resistant mutants that persist after sdNVP are at significantly higher risk of virological failure or death when given NVP-containing ART com- pared with women without detectable NVP resistance by ASP or women given LPV/r-containing ART. Clinical trials have also shown that selection of NVP resistance can be substantially reduced by concomitant suppression of viral replication. McIntyre et al. (14) concluded that supplementing sdNVP with a short course of AZT and 3TC for 4-7 d reduced NVP resistance mutations from 59% in the sdNVP-only group to 9-14%. Treatment with a single dose of TDF/FTC given with sdNVP has also been successful in reducing the frequency of NVP resistance in women (15) . In addition, Lallemant et al. (16) have shown that treatment after sdNVP for 1 mo postpartum with AZT plus didanosine was most efficacious in preventing resistance mutations resulting from sdNVP. Indeed, the international guidelines from the World Health Organization now reflect these major advances in the field and recommend the prophylactic use of sdNVP at the onset of labor and AZT + 3TC for 7 d postpartum. There is an urgent need to expedite the scale-up, implementation, and adherence to these new strategies, in addition to the scale-up of combination ART during pregnancy for treatment-eligible women.
Previous reports have suggested that most women exposed to sdNVP respond well to subsequent NVP-based ART if these women do not initiate therapy for a predetermined amount of time since their sdNVP exposure. One such report concluded that women should wait 6 mo before initiating therapy (11) , another concluded the time interval should be 6-12 mo (10, 17) , and another recommended waiting 18-36 mo (9) before initiating therapy. Each report increased the amount of time recommended to wait before initiating therapy for optimum outcome. Indeed, our data show that the percentage of women with detectable NVP resistance declines with time since sdNVP exposure. In addition, our data show a trend toward declining risk for virological failure of NVP-containing ART with time since sdNVP exposure (Fig. 4) even when no mutations were detected by ASP. However, this trend needs further confirmation because it is quite possible that some of these subjects do have low-frequency NVP-resistant mutations that would contribute to treatment failure but were not tested for by ASP, such as mutations at RT codons 106, 108, and/or 188. In contrast, our data do clearly show that the persistence of NVP-resistant variants, and not the time since sdNVP, is the stronger predictor of response to NVPcontaining ART (Table 4) . Furthermore, because the rate of decay of NVP resistance appears to vary greatly among sdNVPexposed women (6, 7), time since sdNVP exposure is not the best indicator of risk for unfavorable treatment outcome. Time since sdNVP exposure is at best a weak predictor of response to an NVPcontaining regimen, and in the absence of ASP, it may be the only information available for clinical practice, thus underscoring the need to minimize the use of NVP-containing ART in women with a history of receiving sdNVP alone for prevention of MTCT.
Recently, Halvas et al. (18) reported that preexisting resistant variants at frequencies >1% were associated with risk for virological failure in treatment-experienced patients. In agreement with this finding, our data show increased risk for treatment failure associated with 103N and 181C at a mutation frequency of >1% of the virus population.
Our study also reveals that the excess treatment failure observed in the NVP arm is strongly associated with detection of NVP-resistant mutants missed by standard population genotype.
The clinical history of time since last sdNVP exposure alone does not exclude increased risk for unfavorable treatment outcome. Taken together, these findings support MTCT prevention strategies that minimize the emergence of NVP resistance and the use of protease inhibitor-containing regimens in women with prior exposure to sdNVP.
Methods
Sample Collection and Characteristics. The study population was described in detail by Lockman et al. (12) . Baseline plasma samples were collected at the time of study enrollment. Women were randomly assigned to treatment with either NVP + TDF/FTC or LPV/r + TDF/FTC. All participants self-reported prior sdNVP exposure at least 6 mo before enrollment, and 73% had written documentation of sdNVP receipt. All participants provided written informed consent for participation in the trial. All samples were tested without knowledge of treatment arm or results of standard genotype analysis. Testing of samples by ASP was approved by the National Institutes of Health Office of Human Subjects Protection.
Definition of Primary Endpoint. The primary study endpoint was death or virological failure, defined as less than a 1 log 10 drop in plasma HIV-1 RNA copies/mL from baseline by week 12 or HIV-1 RNA >400 copies/mL at or after 24 wk (confirmed in repeat testing), using data through October 6, 2008, when trial 1 results were released as recommended by the data safety monitoring board.
ASP. As reported previously, viral RNA was extracted from baseline plasma samples having HIV-1 RNA of 2,500 copies/mL or greater (19, 20) . cDNA was synthesized, amplified in duplicate, and quantified using subtype-specific real-time PCR. If >1,000 copies per reaction of cDNA were not amplified, as quantified by real-time PCR in comparison with a standard curve, the limits of sensitivity of subsequent ASP assays were adjusted for the number of cDNA copies amplified (<1,000 copies per reaction were obtained for 6 of 232 samples). The products from the first-round real-time PCR were diluted and analyzed by subtype-specific ASP to quantify mutant frequencies of the three most common NVP resistance mutations (K103N, Y181C, and G190A) down to frequencies of 0.1% for codons 103 and 190 and 0.3% for codon 181 as described (7, 21) . In brief, allele-specific primers that selectively amplify mutant or WT alleles were used in a second round of real-time PCR to quantify the proportion of each allele (Table S1 ). Parallel reactions were performed using nonselective primers to quantify total DNA copies amplified. All reactions were performed in duplicate. The percent mutant or WT was calculated by dividing the quantity of mutant or WT copies amplified by the total copies amplified with nonselective primers and multiplying by 100. If the sum of the species detected at any codon was >25% of the total amplified DNA copies, the values were normalized and reported. If the sum of the species detected was less than 25% of the total amplified copies, the assay results are reported as "failed" at that codon (e.g., for codon 103: %AAG + %AAA + %AAC + %AAT < 25%). In the event of failure, the assay was repeated with modified primers and standards as described (21) to achieve a sum of species detecting >25% of the total amplified copies. If the use of alternative primers was not successful in achieving >25%, assay results are reported as "indeterminate" for the alleles tested.
Statistical Analyses. All analyses were intent to treat on women who started study treatment. Cox proportional hazard models were used to compare the hazard (with 95% CIs) of reaching a primary endpoint between subjects with baseline NVP resistance and those without baseline NVP resistance, as well as among women with different time intervals since last exposure to sdNVP. The women who did not reach a primary endpoint were censored at the last available HIV-1 RNA measure by October 6, 2008 . Subjects with baseline NVP resistance were categorized into groups according to NVP mutant frequencies based on the sum of NVP-resistance mutation frequencies across the three codons: no mutant detected, 0.1-<1% mutant, 1-<10% mutant, and ≥10% 
